Literature DB >> 21671685

Reflections on the changing face of German pharmaceutical policy: how far is Germany from value-based pricing?

Andreas Gerber1, Stephanie Stock, Charalabos-Markos Dintsios.   

Abstract

Mesh:

Substances:

Year:  2011        PMID: 21671685     DOI: 10.2165/11592580-000000000-00000

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


× No keyword cloud information.
  1 in total

1.  International prices and availability of pharmaceuticals in 2005.

Authors:  Patricia M Danzon; Michael F Furukawa
Journal:  Health Aff (Millwood)       Date:  2008 Jan-Feb       Impact factor: 6.301

  1 in total
  11 in total

1.  Is it time to reconsider the role of patient co-payments for pharmaceuticals in Europe?

Authors:  Michael Drummond; Adrian Towse
Journal:  Eur J Health Econ       Date:  2012-02

2.  Determinants of Orphan Drug Prices in Germany.

Authors:  Franziska Worm; Charalabos-Markos Dintsios
Journal:  Pharmacoeconomics       Date:  2020-04       Impact factor: 4.981

3.  Pharmaceutical regulation in Europe and its impact on corporate R&D.

Authors:  Stephan Eger; Jörg C Mahlich
Journal:  Health Econ Rev       Date:  2014-10-03

4.  Predictors of negotiated prices for new drugs in Germany.

Authors:  Afschin Gandjour; Sofia Schüßler; Thomas Hammerschmidt; Charalabos-Markos Dintsios
Journal:  Eur J Health Econ       Date:  2020-05-25

5.  Willingness to pay for new medicines: a step towards narrowing the gap between NICE and IQWiG.

Authors:  Afschin Gandjour
Journal:  BMC Health Serv Res       Date:  2020-04-22       Impact factor: 2.655

6.  Cost-effectiveness of Interferon-free therapy for Hepatitis C in Germany--an application of the efficiency frontier approach.

Authors:  Christian Gissel; Georg Götz; Jörg Mahlich; Holger Repp
Journal:  BMC Infect Dis       Date:  2015-07-30       Impact factor: 3.090

7.  Cancer Drug Pricing and Reimbursement: Lessons for the United States From Around the World.

Authors:  Daniel A Goldstein; Michal Sarfaty
Journal:  Oncologist       Date:  2016-07-06

8.  Early decision-analytic modeling - a case study on vascular closure devices.

Authors:  Alina Brandes; Moritz F Sinner; Stefan Kääb; Wolf H Rogowski
Journal:  BMC Health Serv Res       Date:  2015-10-27       Impact factor: 2.655

9.  A proportional rule for setting reimbursement prices of new drugs and its mathematical consistency.

Authors:  Afschin Gandjour
Journal:  BMC Health Serv Res       Date:  2020-03-23       Impact factor: 2.655

10.  Cost-effectiveness of sofosbuvir in hepatitis C genotype 1 infection in Germany: A reanalysis of published results.

Authors:  Afschin Gandjour
Journal:  PLoS One       Date:  2020-10-02       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.